Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 80Head and Neck Neoplasms 72Nasopharyngeal Carcinoma 61Prostatic Neoplasms 51Oropharyngeal Neoplasms 30Carcinoma, Non-Small-Cell Lung 27Rectal Neoplasms 23Carcinoma, Squamous Cell 23Breast Neoplasms 23Glioblastoma 22Uterine Cervical Neoplasms 18Carcinoma 18Neoplasm Metastasis 16Brain Neoplasms 16Nasopharyngeal Neoplasms 15Pancreatic Neoplasms 14Lung Neoplasms 13Gliosarcoma 13Glioma 13Esophageal Neoplasms 13Radiation Injuries 12Mouth Neoplasms 12Laryngeal Neoplasms 12Esophageal Squamous Cell Carcinoma 12Astrocytoma 12Tongue Neoplasms 11Hypopharyngeal Neoplasms 11Sarcoma 10Neoplasms 10Salivary Gland Neoplasms 8

Interventions

bintrafusp alfa protein, human 3Radiotherapy 3Cisplatin 3pembrolizumab 2Gemcitabine 2vactosertib 1fresolimumab 1fludarabine 1enzalutamide 1ascrinvacumab 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Losartan 1Lomustine 1LY3300054 1LY-2157299 1Fenretinide 1Drug Delivery Systems 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1Anastrozole 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Radiotherapy, Intensity-Modulated × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡